06 Confusion between routes Subcutaneous, oral, transdermal, and intranasal AOD-9604 use very different doses
Join now By clicking Continue to join or sign in, you agree to LinkedIns User Agreement, Privacy Policy, and Cookie Policy
Certain health conditions, physiological states, or expectations may increase risk or limit safety
5-Amino-1MQ inhibits NNMT activity, preserving nicotinamide for NAD+ synthesis and preserving SAM for epigenetic methylation producing a metabolic state in pre-clinical models that has been described as functionally resembling caloric restriction or elevated physical activity at the cellular level
Concerns have been raised about serious side effects (e.g., gastrointestinal paralysis)